JanOne was formed in 2019 to find medications that treat diseases with severe pain that result in the potential of prescribing of harmful opioid medications to treat associated pain. It is estimated that 40% of opioid overdose deaths involve prescription opioids, often a direct result to treat those who suffer from chronic pain and neuropathic pain. Our choice was to tackle the issue by treating diseases that cause severe pain at the source so pain is no longer the issue and that means the potential for less opioid prescriptions to treat associated pain. We are fighting opioid abuse at the prescription pad, one disease at a time.
Formerly Appliance Recycling Centers of America, Inc., JanOne is publicly traded on the NASDAQ under the trading symbol JAN. The company has a long history of operating companies with social intent, thus its subsidiary company primarily focused on recycling household appliances and energy efficiency programs.
When we launched JanOne and entered into the world of pharmaceuticals, our aim was to ensure we remained true to maintaining businesses with social responsibility. The result was the creation of a new, dynamic pharmaceutical organization focused on conditions that cause severe pain and to find non-addictive pain reduction alternatives. Our vision is to see a world without pain and that starts with treating diseases that cause pain to millions around the world. If we can treat the disease, we can alleviate associated pain and the need for opioid prescriptions. Ultimately, we hope our efforts lead to the development of non-addictive pain relieving medications to treat the many forms of chronic pain without the risk of addiction, abuse and overdose.
Headquartered in Las Vegas, Nevada, and with access to a global research community, we see a world without pain and work tirelessly towards that goal. We can’t solve that problem alone, but we can certainly have an impact in the years ahead.
On a mission to reduce the need for opioid prescriptions.
Our mission is to bring treatments to the market for diseases that cause severe pain and to find non-addictive answers for treating pain. JanOne – a biotechnology company.
Why? We treat disease at the source and we do our part to reduce the need for opioid prescriptions.
At JanOne, our focus is to treat diseases that cause severe pain at the source and, in the process, we hope to bring non-addictive answers to the market to treat pain. We are starting with Peripheral Artery Disease (PAD), a condition that affects over 8.5 million Americans, many of whom are at risk for addiction when opioids are prescribed to treat the associated pain. JanOne – a biotechnology company.
If we can treat diseases that cause severe pain at the source, we believe we can do our part to reduce opioid addiction at the prescription pad.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for JanOne Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF JanOne Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.